RESUMO
Cancer spread (metastasis) is responsible for 90% of cancer-related fatalities. Informing patient treatment to prevent metastasis, or kill all cancer cells in a patient's body before it becomes metastatic is extremely powerful. However, aggressive treatment for all non-metastatic patients is detrimental, both for quality of life concerns, and the risk of kidney or liver-related toxicity. Knowing when and where a patient has metastatic risk could revolutionize patient treatment and care. In this review, we attempt to summarize the key work of engineers and quantitative biologists in developing strategies and model systems to predict metastasis, with a particular focus on cell interactions with the extracellular matrix (ECM), as a tool to predict metastatic risk and tropism.
RESUMO
Twenty-eight patients with pityriasis versicolor were treated orally with 200 mg of itraconazole per day in an open, randomized comparison of five-day and seven-day treatment regimens. The morphologic changes in Malassezia furfur produced by treatment were confirmed by studies with transmission and scanning electron microscopy. The clinical results showed that seven days of treatment were more effective than five days. Transmission electron microscopy revealed cytopathic changes in the fungus at the end of treatment, intracellular necrosis being complete within seven to 28 days. Cell-surface alterations detected by scanning electron microscopy developed more slowly--maximal changes were observed 14 days after the beginning of treatment. One patient developed nausea during treatment; no other adverse effects were attributed to the drug.
Assuntos
Antifúngicos/uso terapêutico , Cetoconazol/análogos & derivados , Malassezia/efeitos dos fármacos , Tinha Versicolor/tratamento farmacológico , Administração Oral , Adolescente , Adulto , Idoso , Antifúngicos/administração & dosagem , Antifúngicos/farmacologia , Esquema de Medicação , Feminino , Humanos , Itraconazol , Cetoconazol/administração & dosagem , Cetoconazol/farmacologia , Cetoconazol/uso terapêutico , Malassezia/ultraestrutura , Masculino , Microscopia Eletrônica , Microscopia Eletrônica de Varredura , Pessoa de Meia-Idade , Distribuição AleatóriaAssuntos
Tireoidite/diagnóstico , Doença Aguda , Adulto , Idoso , Feminino , Humanos , Radioisótopos do Iodo , Masculino , Pessoa de Meia-Idade , Testes de Função TireóideaAssuntos
Neoplasias da Glândula Tireoide/patologia , Adenocarcinoma/patologia , Adolescente , Adulto , Idoso , Carcinoma/patologia , Carcinoma Papilar/patologia , Criança , Pré-Escolar , Chile , Feminino , Bócio Endêmico/complicações , Humanos , Lactente , Recém-Nascido , Linfoma/patologia , Masculino , Pessoa de Meia-Idade , Neoplasias da Glândula Tireoide/complicações , Neoplasias da Glândula Tireoide/epidemiologiaRESUMO
Se describe un caso de fibrotecoma de ovàrio en una mujer de 48 años, con la presencia de tumoraciòn pèlvica dolorosa y ascitis. Microscopicamente muestra la presencia de cèlulas fusiformes con disposiciòn entrecruzada sin mitosis anormales entremezcladas con nidos de cèlulas tecales. Tumor que se origina en el estroma ovàrico raras veces en un fibroma de, consistencia dura, al corte con aspecto arremolinado blanquesino, con tonos amarillentos, benigno